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Background
Gadolinium-enhanced CMR can be a useful adjunct in the
diagnosis and assessment of acute myocardial infarction
(AMI). However, gadolinium contrast is contraindicated in
severe renal impairment. Alternative, non-gadolinium con-
trast agents for AMI assessment and contrast-enhanced
CMR in general would be of substantial clinical impor-
tance. Ferumoxytol, an intravenous iron-supplementation
drug, was approved in 2009 by the FDA for treatment of
iron-deficiency anemia in patients with chronic kidney dis-
ease, and is known to have T1 shortening properties. The
utility of T1-weighted ferumoxytol-enhanced CMR for
detecting AMI has not been previously evaluated.
Methods
Six canines underwent acute LAD occlusion (70-minutes)
with reperfusion. In-vivo CMR was performed four days
post-MI on a 3.0T scanner in five animals (one animal died
prior to acquisition of images). Clinically available Ferumoxy-
tol (30mg Fe/ml) was administered to provide 5 mg Fe/kg
body weight. Short-axis T1-maps were acquired using a sin-
gle-shot inversion-recovery, gradient-echo sequence with >20
inversion times ranging from 100-3000 ms. Acquisitions
were separated by >10-second delay to allow full recovery of
magnetization, and T1 times were determined by standard
3-parameter iterative curve-fitting. T1 maps were acquired
serially at multiple time-points (5-8) following Ferumoxytol-
injection (range 1-24 hours). Following imaging the hearts
were removed for histopathologic analysis and the presence,
location, and extent of AMI was validated by 2, 3, 5-triphenyl-
tetrazolium chloride (TTC) staining.
Results
All five animals had AMI verified by pathology, and mean
infarct size was 12.7% (range 2.6-16.8%) of LV mass. Feru-
moxytol-kinetics of AMI was complex following two pat-
terns (Figure 1, top). Pattern one (n=3) demonstrated an
early restriction of Ferumoxytol uptake in AMI regions
(approx. 0-2 hrs post Ferumoxytol) compared with normal
myocardium followed later by increased uptake in AMI
relative to normal (approx. 2-6 hrs post), and finally wash-
out of Ferumoxytol in both AMI and normal myocardium
(24 hrs post). Pattern two (n=2) demonstrated reduced
Ferumoxytol uptake compared with normal myocardium
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Figure 1 Difference between normal minus infarcted myocardium.
Pattern one shows the uptake of ferumoxytol contrast. At time 30
min there is non-uptake of contrast - infarct appears black or hypo-
intense. At time 5 hours there is uptake of contrast - infarct appears
whit or hyper-intense. At 24 hours the contrast has washed out of
the infarct.
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throughout all time points (Figure 1, bottom). The abso-
lute difference in T1 between normal myocardium and
AMI over time averaged for the five animals is shown in
Figure 2. In 20 of 27 time-points (74%), the absolute T1-
difference was >100ms, which was sufficient to visualize
AMI on routine inversion-recovery CMR.
Conclusions
Ferumoxytol kinetics in AMI are complex and may reflect
either reduced or increased contrast uptake depending on
time post contrast administration. However, AMI can
consistently be detected by Ferumoxytol-enhanced CMR
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Figure 2 Absolute Difference in T1 between Normal and Infarcted
Myocardium (ms) over Time after administration of Ferumoxytol
contrast.
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